Amarin Corp Plc (AMRN)

[HinduKush]

Kiwi
(1) Prescribers need a lipid panel that's recent-most third-party payors insist on <3 months, and a patient on maximally tolerated" statin dose with a residual elevated TG>150
(2) The TG >500 mg/dl cohort gets automatically prior authorized for Vascepa, though some HMO's insist on substituting generic omega 3 ethyl esters eg Lovaza since we claim that we are treating hypertriglyceridemia and not preventing CAD/CVD.
(3) The TG<500 and >150 mg/dl pprimary/secondary prevention cohort are then eligible for Vascepa IF they have diabetes on a maximally tolerated statin and TG>150 mg/dl OR any evidence of established CAD CVD PAD demonstrated either by direct imaging eg vascular ultrasound or coronary artery CT angiography or conventional direct contrast injection angiography, non-invasive testing e.g. abnormal Ankle Brachial Index, abnormal stress imaging OR clinical events eg MI STENT CVA PAD with gangrene or needing vascular intervention etc...
(4) Far far more of these prescriptions will emerge from the outpatient screening arena than ever from the ER or post-hospital admission because the focus there is not on prevention but immediate medical therapy and discharge...
HK